Summary
Lonidamine is an indazole carboxylic acid that has been shown to be synergistic with radiotherapy (RT) in tissue culture and animal models. Clinical experience has shown that lonidamine is well-tolerated, and appears to potentiate the activity of conventional chemotherapy in the treatment of brain metastases. A prospective randomized trial was undertaken to evaluate the use of lonidamine in combination with RT in the treatment of brain metastases. All patients received 3000 cGy of whole brain radiotherapy (WBRT). Fifty eight patients were enrolled; 31 received lonidamine plus WBRT and 27 received WBRT alone. There was no significant difference in response rate or survival between the treatment groups. Lonidamine blood levels were measured in 30 of the 31 patients who received the drug, and were therapeutic (⩾ 15 μg/ml) in 50%. Survival and response rate were unaffected by the presence or absence of a therapeutic lonidamine level. The most common side-effects of lonidamine were myalgia, testicular pain, anorexia, and ototoxicity; however, only 2 patients had to discontinue the drug because of intolerable myalgias. No serious organ toxicity or myelosuppression was observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Posner JB, Chernik NL: Intracranial metastases from systemic cancer. Advances in Neurol 19: 579–592, 1978
Posner, JB: Management of central nervous system metastases. Sem Oncol 4: 81–91, 1977
Cairncross JG, Kim JH, Posner JB: Radiation therapy for brain metastases. Ann Neurol 7: 529–541, 1980
Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, David LW, Perez CA, Hendrickson FR: The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int J Radiation Oncol Biol Phys 6: 1–8, 1980
Eyre HJ, Ohlsen JD, Frank J, LoBuglio AF, McCracken JD, Weatherall TJ, Mansfield CM: Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer the brain. J Neuro One 2: 325–330, 1984
Aiken R, Leavengood JM, Kim JH, Deck MDF, Thaler HT, Posner JB: Metronidazole in the treatment of metastatic brain tumors. J Neuro One 2: 105–110, 1984
Caputo A, Silvestrini B: Lonidamine, a new approach to cancer therapy. Oncology 41: (Suppl 1) 2–6, 1984
DeMartino C, Battelli T, Paggi MG, Nista A, Marcante ML, D'Atri S, Malorni W, Gallo M, Floridi A: Effects of Lonidamine on Murine and human tumor cells in vitro. Oncology 41: (Suppl 1) 15–29, 1984
Kim JH, Alfieri A, Kim SH, Young CW, Silvestrini B: Radiosensitization of Meth-A fibrosarcoma in mice by Lonidamine. Oncology 41: (Suppl 1) 36–38, 1984
Kim JH, Alfieri AA, Kim SH and Young CW: The potentiation of radiation effects on two murine tumors by Ionidamine. Cancer Res 46: 1120–1123, 1986
Magno L, Terraneo F, Ciottoli GB: Lonidamine and radiotherapy in head and neck cancers: a pilot study. Oncology 41: (Suppl 1) 113–115, 1984
Magno L, Terraneo F, Scandolaro L, Bertoni F, DeGregorio M, Ciottoli GB: Lonidamine (L) and radiotherapy in head and neck cancer: a preliminary report. Proc Amer Soc Clin Oncol 6: 126, 1987
Privitera G, Ciottoli GB, Patane C, Palmucci T, Tafuri G, Marletta F, DeLuca B, Magnani F, DeGregorio M, Greco S; Phase II double-blind randomized study of Ionidamine and radiotherapy in epidermoid carcinoma of the lung. Radiother Oncol 10: 285–290, 1987.
Battelli T, Manocchi P, Giustini L, Mattioli R, Ginnetti A, DeGregorio M, De Martino C, Silvestrini B: A long-term clinical experience with Lonidamine. Oncology 41: (Suppl 1) 39–47, 1984
Besner JG, Leclaire R, Band PR, Deschamps M, DeSanctis AJ, Catanese B: Pharmacokinetics of Lonidamine after oral administration in cancer patients. Oncology 41: (Suppl 1) 48–51, 1984
Kaplan EL, Meier P: Non-parametric estimations from incomplete observations. J Am Stat Assoc 53: 457–481, 1958
Young CW, Currie VE, Kim JH, O'Hehir MA, Farag FM, Kinahan JE: Phase I and clinical pharmacologic evaluation of lonidamine in patients with advanced cancer. Oncology 41: (Suppl 1) 60–65, 1984
Band PR, Deschamps M, Besner J-G, Leclaire R, Gervais P, DeSanctis A: Phase II study of lonidamine in cancer patients. Oncology 41: (Suppl 1) 66–68, 1984
Evans WK, Shepherd FA, Mullis B: Phase II evaluation of lonidamine in patients with advanced malignancy. Oncology 41: (Suppl 1) 69–77, 1984
Hahn GM, van Kersen I, Silvestrini B: Inhibition of the recovery from potentially lethal damage by lonidamine. Br J Cancer 50: 657–660, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeAngelis, L.M., Currie, V.E., Kim, JH. et al. The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J Neuro-Oncol 7, 241–247 (1989). https://doi.org/10.1007/BF00172917
Issue Date:
DOI: https://doi.org/10.1007/BF00172917